Table 1.
Baseline Donor Characteristics
| Placebo (N = 246) |
Albuterol (N = 260) |
|
|---|---|---|
| Age (yrs) | 42 ± 15 | 43 ± 16 |
| Male | 161 (65%) | 158 (61%) |
| Race/ethnicity | ||
| -Caucasian | 145 (59%) | 159 (61%) |
| -Hispanic | 60 (24%) | 52 (20%) |
| -African American | 20 (8%) | 31 (12%) |
| -Asian | 19 (8%) | 16 (6%) |
| Current smoker | 112 (46%) | 106 (41%) |
| Cause of brain injury | ||
| -head trauma | 106 (43%) | 102 (39%) |
| -CVA/bleed | 95 (39%) | 111 (43%) |
| -anoxic injury | 43 (18%) | 40 (15%) |
| -other | 2 (1%) | 7 (3%) |
| Current lung disease | 17 (7%) | 31 (12%) |
| Time from clinical brain stem herniation to enrollment (h) | 26 ± 22 | 26 ± 24 |
| Albuterol treatment prior to enrollment | 59 (24%) | 59 (23%) |
| Tidal volume (ml/kg) | 8.9 ± 1.7 | 8.7 ± 1.8 |
| Positive end expiratory pressure (cm H2O) | 5.7 ± 1.9 | 5.9 ± 2.2 |
| Creatinine (mg/dL) | 1.28 ± 0.96 | 1.34 ± 1.20 |
Data as mean ± SD or N (%)